WO2013032558A4 - Products for anti-inflammation support - Google Patents
Products for anti-inflammation support Download PDFInfo
- Publication number
- WO2013032558A4 WO2013032558A4 PCT/US2012/042009 US2012042009W WO2013032558A4 WO 2013032558 A4 WO2013032558 A4 WO 2013032558A4 US 2012042009 W US2012042009 W US 2012042009W WO 2013032558 A4 WO2013032558 A4 WO 2013032558A4
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- product
- vitamin
- carbon
- anatabine
- alkyl
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title 1
- 239000000047 product Substances 0.000 claims abstract 20
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract 2
- 235000015872 dietary supplement Nutrition 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 229910052799 carbon Inorganic materials 0.000 claims 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 7
- SOPPBXUYQGUQHE-JTQLQIEISA-N Anatabine Chemical compound C1C=CCN[C@@H]1C1=CC=CN=C1 SOPPBXUYQGUQHE-JTQLQIEISA-N 0.000 claims 5
- SOPPBXUYQGUQHE-UHFFFAOYSA-N Anatabine Natural products C1C=CCNC1C1=CC=CN=C1 SOPPBXUYQGUQHE-UHFFFAOYSA-N 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 229940088594 vitamin Drugs 0.000 claims 3
- 229930003231 vitamin Natural products 0.000 claims 3
- 235000013343 vitamin Nutrition 0.000 claims 3
- 239000011782 vitamin Substances 0.000 claims 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims 3
- 235000005282 vitamin D3 Nutrition 0.000 claims 3
- 239000011647 vitamin D3 Substances 0.000 claims 3
- 229940021056 vitamin d3 Drugs 0.000 claims 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 235000019155 vitamin A Nutrition 0.000 claims 2
- 239000011719 vitamin A Substances 0.000 claims 2
- 229940045997 vitamin a Drugs 0.000 claims 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 239000004376 Sucralose Substances 0.000 claims 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 239000008368 mint flavor Substances 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims 1
- 235000019408 sucralose Nutrition 0.000 claims 1
- 239000004408 titanium dioxide Substances 0.000 claims 1
- 235000010215 titanium dioxide Nutrition 0.000 claims 1
- 239000001069 triethyl citrate Substances 0.000 claims 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims 1
- 235000013769 triethyl citrate Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
This disclosure provides products, including pharmaceutical compositions and dietary supplements, which are useful for anti-inflammatory support.
Claims
AMENDED CLAIMS
received by the International Bureau on 07 October 2013 (07.10.2013).
1. A product comprising: a compound of Formula I
Formula I wherein R represents hydrogen or C1 - C5 alkyl; R' represents hydrogen or C1 - C7 alkyl; and X represents halogen or Ci - C7 alkyl, or a pharmaceutically acceptable salt thereof; and the dotted line within piperidine ring B represents a carbon/carbon or carbon/nitrogen double bond or two conjugated double bonds selected independently from a carbon/nitrogen double bond and a carbon/carbon double bonds, wherein: when a carbon/nitrogen double bond is present, R is absent; and either:
(i) "a" is an integer ranging from 1-4 and "b" is an integer ranging from 0-8; or
(ii) "a" is an integer ranging from 0-4 and "b" is an integer ranging from 1-8, and
wherein when a carbon/nitrogen double bond is not present, R is present; "a" is an integer ranging from 0-4; and "b" is an integer ranging from 0-8; and
(b) a vitamin.
2 The product of claim 1, wherein R represents hydrogen or Ci - C3 alkyl.
3 The product of claim 1 or claim 2, wherein R' represents hydrogen or Ci - C4 alkyl.
4. The product of claim 1, claim 2, or claim 3, wherein X represents halogen or C1 -
C3 alkyl.
5. The product of claim 1, wherein the compound is anatabine.
6. The product of claim 5, wherein the compound is S-(-)-anatabine.
7. The product of claim 5, wherein the compound is R-(+)-anatabine.
8. The product of any of claims 1-7, wherein the vitamin is Vitamin A.
9. The product of any of claims 1-7, wherein the vitamin is Vitamin D3.
10. The product of any of claims 1-7, further comprising Vitamin D3.
11. The product of any of claims 5-10, wherein the anatabine is synthetic anatabine.
12. The product of any of claims 5-10, wherein the anatabine is provided in the form of an extract from a plant.
13. The product of any of claims 5-12 which comprises anatabine in an amount of about 1 mg.
14. The product of any of claims 1-13, which comprises Vitamin A in an amount of about 417 IU.
15. The product of any of claims 1-13, comprising Vitamin D3 in an amount of about
33 IU.
16
16. The product of any of claims 1-15, further comprising one or more additional ingredients selected from the group consisting of mannitol, natural and artificial mint flavors, sucralose, silicon dioxide, stearic acid, hydroxypropyl methylcellulose, magnesium stearate, titanium dioxide, natural glaze, methyl parabens, propylparabens, triethyl citrate, citric acid, BHT, mono and diglycerides, and polysorbate 80.
17. The product of any of claims 1-16 which is a dietary supplement.
18. The product of any of claims 1-16 which is a pharmaceutical composition.
19. A method of providing anti-inflammatory support, comprising administering to an individual in need thereof the product of any of claims 1-18.
20. The method of claim 19 wherein the individual is human.
17
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012302257A AU2012302257A1 (en) | 2011-08-29 | 2012-06-12 | Products for anti-inflammation support |
| CA2847199A CA2847199C (en) | 2011-08-29 | 2012-06-12 | Product comprising anatabine or salts thereof, vitamin a and vitamin d3 and pharmaceutical compositions thereof used for anti-inflammation support |
| EP12828051.8A EP2751091A4 (en) | 2011-08-29 | 2012-06-12 | Products for anti-inflammation support |
| JP2014528385A JP5934796B2 (en) | 2011-08-29 | 2012-06-12 | Anti-inflammatory products |
| CN201280053394.6A CN104169269A (en) | 2011-08-29 | 2012-06-12 | Products for anti-inflammation support |
| KR1020147007996A KR20140124354A (en) | 2011-08-29 | 2012-06-12 | Products for anti-inflammation support |
| HK15100215.2A HK1199733A1 (en) | 2011-08-29 | 2015-01-08 | Products for anti-inflammation support |
| AU2018202701A AU2018202701B2 (en) | 2011-08-29 | 2018-04-18 | Products for anti-inflammation support |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161528380P | 2011-08-29 | 2011-08-29 | |
| US61/528,380 | 2011-08-29 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2013032558A2 WO2013032558A2 (en) | 2013-03-07 |
| WO2013032558A3 WO2013032558A3 (en) | 2013-09-26 |
| WO2013032558A4 true WO2013032558A4 (en) | 2013-11-21 |
Family
ID=47744572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2012/042009 WO2013032558A2 (en) | 2011-08-29 | 2012-06-12 | Products for anti-inflammation support |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20130053355A1 (en) |
| EP (1) | EP2751091A4 (en) |
| JP (1) | JP5934796B2 (en) |
| KR (1) | KR20140124354A (en) |
| CN (2) | CN108578405A (en) |
| AU (2) | AU2012302257A1 (en) |
| CA (1) | CA2847199C (en) |
| HK (1) | HK1199733A1 (en) |
| WO (1) | WO2013032558A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019407661A1 (en) * | 2018-12-17 | 2021-04-29 | Philip Morris Products S.A. | 3-(1,2,3,6-tetrahydropyridin-2-yl)pyridine glutarate or a pharmaceutically acceptable solvate thereof |
| WO2021249608A2 (en) * | 2020-06-09 | 2021-12-16 | Elkazaz Mohamed Fadly Abd El Ghany | A novel medicament for immune modulation and treating chronic or hyper inflammation |
| KR20230024889A (en) | 2020-06-15 | 2023-02-21 | 필립모리스 프로덕츠 에스.에이. | Anatarbine Powder Composition |
| WO2022049487A1 (en) | 2020-09-03 | 2022-03-10 | Philip Morris Products S.A. | Low hygroscopicity active powder compositions |
| MX2023002467A (en) | 2020-09-03 | 2023-03-23 | Philip Morris Products Sa | Spray dried low hygroscopicity active powder compositions. |
| WO2022049486A1 (en) | 2020-09-03 | 2022-03-10 | Philip Morris Products S.A. | Freeze dried low hygroscopicity active powder compositions |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2930720A (en) | 1958-05-07 | 1960-03-29 | Erb Tobacco Products Co Inc | Smoking composition |
| US3067068A (en) | 1959-03-09 | 1962-12-04 | E R B Tobacco Products Co Inc | Tobacco-like composition |
| US3901248A (en) | 1970-07-22 | 1975-08-26 | Leo Ab | Chewable smoking substitute composition |
| US4897388A (en) * | 1988-12-20 | 1990-01-30 | Geriatric Research Institute, Inc. | Method of treating Alzheimer's disease |
| US5525351A (en) | 1989-11-07 | 1996-06-11 | Dam; Anders | Nicotine containing stimulant unit |
| US5512306A (en) | 1992-06-19 | 1996-04-30 | Pharmica Ab | Smoking substitute |
| DE4002784C1 (en) | 1990-01-31 | 1991-04-18 | B.A.T. Cigarettenfabriken Gmbh, 2000 Hamburg, De | |
| US5065775A (en) | 1990-02-23 | 1991-11-19 | R. J. Reynolds Tobacco Company | Tobacco processing |
| KR0175638B1 (en) | 1991-03-01 | 1999-02-18 | 카렌 에이.홀브루크 | Use of nicotinic analogs for treatment of degenerative diseases of the nervous system |
| US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| US5276043A (en) | 1992-04-10 | 1994-01-04 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| US5573774A (en) | 1993-02-02 | 1996-11-12 | Keenan; Robert M. | Nicotine metabolites, nicotine dependence and human body weight |
| US5387416A (en) | 1993-07-23 | 1995-02-07 | R. J. Reynolds Tobacco Company | Tobacco composition |
| US6311695B1 (en) | 1996-06-28 | 2001-11-06 | Regent Court Technologies | Method of treating tobacco to reduce nitrosamine content, and products produced thereby |
| US5845647A (en) | 1996-06-28 | 1998-12-08 | Regent Court Technologies | Tobacco and related products |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| US5792799A (en) | 1996-10-10 | 1998-08-11 | Athena Neurosciences, Inc. | Parenteral delivery of MAO A inhibitors |
| US6202649B1 (en) | 1996-12-02 | 2001-03-20 | Regent Court Technologies | Method of treating tobacco to reduce nitrosamine content, and products produced thereby |
| US5760049A (en) | 1997-02-21 | 1998-06-02 | Synapse Pharmaceuticals International, Inc. | Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use |
| US6166032A (en) | 1997-02-07 | 2000-12-26 | Synapse Pharmaceuticals International, Inc. | Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use |
| US6210710B1 (en) | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
| US5942244A (en) | 1997-07-31 | 1999-08-24 | Farmo-Nat Ltd. | Local oral herbal slow release tablets |
| CN1318041C (en) | 1997-12-08 | 2007-05-30 | 自然医师技术股份有限公司 | Compositions for weight reduction |
| US6090411A (en) | 1998-03-09 | 2000-07-18 | Temple University | Monolithic tablet for controlled drug release |
| AU770309B2 (en) | 1998-06-05 | 2004-02-19 | Regent Court Technologies | Monoamine oxidase (MAO) inhibitors and uses thereof |
| US6497234B1 (en) | 1999-11-22 | 2002-12-24 | Pamela Coy-Herbert | Herbal composition as a substitute for tobacco |
| US6448276B1 (en) | 2000-05-17 | 2002-09-10 | Inspire Pharmaceuticals, Inc. | Method for treating vaginal dryness with nicotinic acetylcholine receptor agonists |
| US6534527B2 (en) | 2000-06-02 | 2003-03-18 | Phytos, Inc. | Edible herbal compositions for relieving nicotine craving |
| US8519005B2 (en) | 2000-07-27 | 2013-08-27 | Thomas N. Thomas | Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy |
| US6369052B1 (en) * | 2000-08-07 | 2002-04-09 | Georgetown University | Combination of huperzine and nicotinic compounds as a neuroprotective agent |
| CA2341952A1 (en) | 2001-03-23 | 2002-09-23 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases |
| US6541043B2 (en) * | 2001-08-28 | 2003-04-01 | Dexgen Pharmaceuticals, Inc. | Method and synergistic composition for treating attention deficit/hyperactivity disorder |
| US6582737B2 (en) | 2001-09-25 | 2003-06-24 | Peirce Management, Llc | Pharmaceutical composition containing two active ingredients for smoking cessation |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| DE60224832T2 (en) | 2001-12-21 | 2009-01-22 | Galenica Ab | TOBACCO AND / OR TOBACCO IN COMBINATION WITH TOBACCO SUBSTITUTE COMPOSITION FOR USE AS A BUTCH IN THE MOUTH VALVE |
| US20040013752A1 (en) | 2002-07-05 | 2004-01-22 | Wolfson Philip E. | Buccal and sublingual mucosally absorbed herbal compositions for relieving nicotine withdrawal symptoms and craving for nicotine and nicotine containing substances |
| US20070003636A1 (en) | 2003-01-22 | 2007-01-04 | Francois Mach | Statins (HMG-COA reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent |
| US7115285B2 (en) | 2003-03-14 | 2006-10-03 | Eurark, Llc | Composition and method for appetite and craving suppression and mood enhancement |
| US7294353B2 (en) | 2003-10-24 | 2007-11-13 | Herbalscience, Llc | Methods and compositions comprising ilex |
| US7279184B2 (en) | 2003-10-24 | 2007-10-09 | Herbalscience, Llc | Methods and compositions comprising Ilex |
| US20060004076A1 (en) | 2004-06-30 | 2006-01-05 | Inflabloc Pharmaceuticals, Inc. | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation |
| WO2006034463A2 (en) | 2004-09-23 | 2006-03-30 | Herbalife International, Inc. | Herbal supplement to support weight loss |
| CA2736871C (en) | 2008-09-11 | 2019-03-12 | Catholic Healthcare West | Nicotinic attenuation of cns inflammation and autoimmunity |
| US8151804B2 (en) | 2008-12-23 | 2012-04-10 | Williams Jonnie R | Tobacco curing method |
| US8360072B2 (en) * | 2009-10-09 | 2013-01-29 | Philip Morris Usa Inc. | Combination treatment of tobacco extract using antioxidants and antioxidant scavengers |
| DK2549995T3 (en) * | 2010-03-23 | 2021-05-25 | Philip Morris Products Sa | USE OF ANATABINE FOR THE TREATMENT OF INFLAMMATION AND METHODS FOR SYNTHETIZING ANATABINE |
| US8207346B2 (en) * | 2010-03-23 | 2012-06-26 | Rock Creek Pharmaceuticals, Inc. | Methods of synthesizing anatabine |
| US20120196899A1 (en) | 2010-09-17 | 2012-08-02 | Rock Creek Pharmaceuticals, Inc. | Methods and products for treating inflammation |
| US20120245202A1 (en) | 2010-09-17 | 2012-09-27 | Rock Creek Pharmaceuticals, Inc. | Methods and products for treating inflammation |
-
2012
- 2012-06-12 CN CN201711326377.6A patent/CN108578405A/en active Pending
- 2012-06-12 KR KR1020147007996A patent/KR20140124354A/en not_active Application Discontinuation
- 2012-06-12 JP JP2014528385A patent/JP5934796B2/en active Active
- 2012-06-12 CN CN201280053394.6A patent/CN104169269A/en active Pending
- 2012-06-12 WO PCT/US2012/042009 patent/WO2013032558A2/en unknown
- 2012-06-12 US US13/494,237 patent/US20130053355A1/en not_active Abandoned
- 2012-06-12 EP EP12828051.8A patent/EP2751091A4/en not_active Withdrawn
- 2012-06-12 AU AU2012302257A patent/AU2012302257A1/en not_active Abandoned
- 2012-06-12 CA CA2847199A patent/CA2847199C/en active Active
-
2014
- 2014-01-29 US US14/167,285 patent/US9387201B2/en active Active
-
2015
- 2015-01-08 HK HK15100215.2A patent/HK1199733A1/en unknown
-
2018
- 2018-04-18 AU AU2018202701A patent/AU2018202701B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104169269A (en) | 2014-11-26 |
| CN108578405A (en) | 2018-09-28 |
| HK1199733A1 (en) | 2015-07-17 |
| EP2751091A4 (en) | 2015-03-11 |
| US9387201B2 (en) | 2016-07-12 |
| JP2014529622A (en) | 2014-11-13 |
| US20130053355A1 (en) | 2013-02-28 |
| US20140206656A1 (en) | 2014-07-24 |
| AU2018202701A1 (en) | 2018-07-05 |
| CA2847199C (en) | 2022-03-22 |
| AU2012302257A1 (en) | 2014-03-13 |
| JP5934796B2 (en) | 2016-06-15 |
| AU2018202701B2 (en) | 2019-11-21 |
| KR20140124354A (en) | 2014-10-24 |
| WO2013032558A2 (en) | 2013-03-07 |
| WO2013032558A3 (en) | 2013-09-26 |
| CA2847199A1 (en) | 2013-03-07 |
| EP2751091A2 (en) | 2014-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013032558A4 (en) | Products for anti-inflammation support | |
| WO2012035559A3 (en) | Sustained release pharmaceutical compositions comprising pregabalin | |
| NZ703564A (en) | Oral formulations and lipophilic salts of methylnaltrexone | |
| WO2009046865A3 (en) | Cholecystokinin-33 alone or in combination with trap-14 as therapeutic agent | |
| WO2009040036A3 (en) | Use of a galanin peptide as a therapeutic agent | |
| TN2012000362A1 (en) | Rifaximin powder, process for preparing the same and controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect | |
| WO2009033799A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009046859A3 (en) | Use of af12198 and dago as therapeutic agents | |
| WO2009043506A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009043507A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009033667A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009043464A3 (en) | Astressin and beta- endorphin for use as therapeutic agents | |
| UA105766C2 (en) | Pharmaceutical composition comprising a strontium salt, vitamin d and a cyclodextrin | |
| WO2009033767A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009046867A3 (en) | Caerulein alone or in combination with acth (3-24 ) as therapeutic agent | |
| WO2009040021A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009040028A3 (en) | Use of casoxin c and optionally adrenomedullin as therapeutic agents for the treatment of excessive angiogenesis | |
| WO2009033769A3 (en) | Use of cortistatin 14 and others as a therapeutic agent | |
| WO2009040017A3 (en) | Use of a peptide as a therapeutic agent | |
| MX2022000774A (en) | Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof. | |
| JO3008B1 (en) | Pharmaceutical Composition For Relieving Pain | |
| WO2009033750A3 (en) | Use of phm-27 alone or in combination with leu-enkephalin as a therapeutic agent | |
| WO2009033748A3 (en) | Use of osteostatin, alone or in combination with thymopentin, as a therapeutic agent | |
| MX2020002078A (en) | Amantadine compositions, preparations thereof, and methods of use. | |
| WO2011019735A3 (en) | Nutritional supplements |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENP | Entry into the national phase |
Ref document number: 2014528385 Country of ref document: JP Kind code of ref document: A Ref document number: 2847199 Country of ref document: CA |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2012302257 Country of ref document: AU Date of ref document: 20120612 Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 20147007996 Country of ref document: KR Kind code of ref document: A |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12828051 Country of ref document: EP Kind code of ref document: A2 |